US CNS Disorders Drug Pipeline Insight 2014 - Beckley, Bluefield & Lewisburg News, Weather, Sports

US CNS Disorders Drug Pipeline Insight 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering.

600769

The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

Key Topics Covered:

1. Introduction to Central Nervous System (CNS) Disorder

2. US Central Nervous System (CNS) Disorder Market Overview

3. US Central Nervous System (CNS) Disorder Incidence by Disease

4. US Central Nervous System (CNS) Disorder Market Dynamics

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company

6. US Alzheimer's Disease Drug Pipeline by Phase & Company

7. US Multiple Sclerosis Drug Pipeline by Phase & Company

8. US Parkinson's Disease Drug Pipeline by Phase & Company

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company

10. US Epilepsy Drug Pipeline by Phase & Company

11. US Migraine Drug Pipeline by Phase & Company

12. US Huntington's Disease Drug Pipeline by Phase & Company

13. US Neuropathic Pain Clinical Pipeline by Phase & Company

14. US Schizophrenia Clinical Trial Insight by Phase & Company

15. US Sleep Disorders Drug Pipeline by Phase & Company

16. Competitive Landscape

Companies Mentioned:

  • Alkermes
  • Allergan
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/vtvc8r/us_cns_disorders

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

©2012 PR Newswire. All Rights Reserved.